Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer. (16th March 2021)

• Record Type: Journal Article
• Authors: Pramod, Nikhil; Nigam, Akanksha; Basree, Mustafa; Mawalkar, Resham; Mehra, Saba; Shinde, Neelam; Tozbikian, Gary; Williams, Nicole; Majumder, Sarmila; Ramaswamy, Bhuvaneswari
• Is Part Of: Oncologist. Volume 26:Number 6(2021)
• Page Start: e943
• Page End: e953
• Publication Date: 2021-03-16
• Subjects: Lobular cancer -- E-cadherin -- Dormancy -- Late recurrence -- ERBB2; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1002/onco.13734
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : : Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancers in the United States, 80% of which are estrogen receptor (ER)-positive, with an unusual metastatic pattern of spread to sites such as the serosa, meninges, and ovaries, among others. Lobular cancer presents significant challenges in detection and clinical management given its multifocality and multicentricity at presentation. Despite the unique features of ILC, it is often lumped with hormone receptor-positive invasive ductal cancers (IDC); consequently, ILC screening, treatment, and follow-up strategies are largely based on data from IDC. Despite both being treated as ER-positive breast cancer, querying the Cancer Genome Atlas database shows distinctive molecular aberrations in ILC compared with IDC, such as E-cadherin loss (66% vs. 3%), FOXA1 mutations (7% vs. 2%), and GATA3 mutations (5% vs. 20%). Moreover, compared with patients with IDC, patients with ILC are less likely to undergo breast-conserving surgery, with lower rates of complete response following therapy as these tumors are less chemosensitive. Taken together, this suggests that ILC is biologically distinct, which may influence tumorigenesis and therapeutic strategies. Long-term survival and clinical outcomes in patients with ILC are worse than in stage- and grade-matched patients with IDC; therefore, nuanced criteria are needed to better define treatment goals and protocols tailored to ILC's unique biology. This comprehensive review highlights the histologic and clinicopathologic features that distinguish ILC from IDC, with an in-depth discussion of ILC's molecular alterations and biomarkers, clinical trials and treatment strategies, and future targets for therapy. Implications for Practice: The majority of invasive lobular breast cancers (ILCs) are hormone receptor (HR)-positive and low grade. Clinically, ILC is treated similar to HR-positive invasive ductal cancer (IDC). However, ILC differs distinctly from IDC in its clinicopathologic characteristics and molecular alterations. ILC also differs in response to systemic therapy, with studies showing ILC as less sensitive to chemotherapy. Patients with ILC have worse clinical outcomes with late recurrences. Despite these differences, clinical trials treat HR-positive breast cancers as a single disease, and there is an unmet need for studies addressing the unique challenges faced by patients diagnosed with ILC. Abstract : Invasive lobular carcinoma is the second most common subtype of invasive breast cancer and presents unique challenges in detection and treatment. This review reports on the distinct morphological, molecular, and clinical features of invasive lobular carcinoma and highlights the challenges in the management of this cancer.